Together, these findings identify NR4A1 as a negative regulator of CD8<sup>+</sup> T cell-mediated immunity in TB and suggest the NR4A1-NKG7 axis as a novel host-directed therapeutic target. This evidence concerns the gene CD8A and tuberculosis.